Table 3. Relationships between cardiovascular proteins and prevalent plaque.
Thirteen proteins were identified in the discovery phase and were evaluated in the validation step. This table show the 12 proteins with FDR<5% in the validation step following adjustment for age and sex. Also data following further adjustment for cardiovascular (CV) risk factors are shown. The betas are the log odds ratios. We demanded the multiple-adjusted p-value to be <0.05 in order to claim that the relationship between a protein and an outcome was significant.
| Age and sex-adjusted | Also adjusted for CV risk factors | |||||
|---|---|---|---|---|---|---|
| Protein | Beta | SE | p-value | Beta | SE | p-value |
| Matrix metalloproteinase-12 (MMP-12) | .25 | .031 | 5.58e-16 | .20 | .03 | 5.12e-10 |
| Growth/differentiation factor 15 (GDF-15) | .21 | .034 | 6.86e-10 | .16 | .038 | 9.16e-06 |
| T-cell immunoglobulin and mucin domain 1 (TIM-1) | .15 | .030 | 5.54e-07 | .11 | .033 | .00046 |
| Interleukin-6 (IL-6) | .13 | .030 | .000013 | .10 | .032 | .0020 |
| Urokinase plasminogen activator surface receptor (U-PAR) | .12 | .03 | .000034 | .095 | .031 | .0025 |
| TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) | .11 | .032 | .00032 | .094 | .034 | .0060 |
| Lectin-like oxidized LDL receptor 1 (LOX-1) | .10 | .030 | .00051 | .072 | .032 | .024 |
| Matrix metalloproteinase-10 (MMP-10) | .095 | .029 | .0010 | .0797 | .03 | .0094 |
| Hepatocyte growth factor (HGF) | .091 | .030 | .0024 | .048 | .033 | .14 |
| Stem cell factor (SCF) | −.086 | .029 | .0035 | −.028 | .031 | .37 |
| Leptin (LEP) | −.094 | .034 | .0056 | −.157 | .047 | .00095 |
| Galanin peptides (GAL) | −.070 | .030 | .020 | −.021 | .032 | .51 |